Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients (Sweapea)
A Double-blind, Placebo-controlled, Randomised, Parallel-group, Phase II, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of 4 Twice Daily Doses and 2 Once Daily Doses of AZD1981 Given as Tablets During 12 Weeks in Asthmatic Patients
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Fase
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Buenos Aires, Argentina
- Research Site
-
Mendoza, Argentina
- Research Site
-
-
Buenos Aires
-
Quilmes, Buenos Aires, Argentina
- Research Site
-
-
Santa Fe
-
Rosario, Santa Fe, Argentina
- Research Site
-
-
Tucuman
-
San Miguel de Tucuman, Tucuman, Argentina
- Research Site
-
-
-
-
Brasil
-
Porto Alegre, Brasil, Brasil
- Research Site
-
-
ES
-
Vitoria, ES, Brasil
- Research Site
-
-
MG
-
Belo Horizonte, MG, Brasil
- Research Site
-
Juiz de Fora, MG, Brasil
- Research Site
-
-
RS
-
Porto Alegre, RS, Brasil
- Research Site
-
-
SP
-
Santo Andre, SP, Brasil
- Research Site
-
Sao Paulo, SP, Brasil
- Research Site
-
-
Santa Catarina
-
Florian Polis, Santa Catarina, Brasil
- Research Site
-
-
-
-
-
Banska Bystrica, Eslovaquia
- Research Site
-
Bardejov, Eslovaquia
- Research Site
-
Bratislava, Eslovaquia
- Research Site
-
Dunajska Streda, Eslovaquia
- Research Site
-
Hnusta, Eslovaquia
- Research Site
-
Komarno, Eslovaquia
- Research Site
-
Kosice, Eslovaquia
- Research Site
-
Levice, Eslovaquia
- Research Site
-
Liptovsky Hradok, Eslovaquia
- Research Site
-
Liptovsky Mikulas, Eslovaquia
- Research Site
-
Presov, Eslovaquia
- Research Site
-
Rimavska Sobota, Eslovaquia
- Research Site
-
Ruzomberok, Eslovaquia
- Research Site
-
Trencin, Eslovaquia
- Research Site
-
Zvolen, Eslovaquia
- Research Site
-
-
-
-
California
-
Fullerton, California, Estados Unidos
- Research Site
-
Los Angeles, California, Estados Unidos
- Research Site
-
Mission Viejo, California, Estados Unidos
- Research Site
-
Rolling Hills Estates, California, Estados Unidos
- Research Site
-
San Diego, California, Estados Unidos
- Research Site
-
San Jose, California, Estados Unidos
- Research Site
-
-
Maryland
-
Wheaton, Maryland, Estados Unidos
- Research Site
-
-
Massachusetts
-
North Dartmouth, Massachusetts, Estados Unidos
- Research Site
-
-
Nebraska
-
Bellevue, Nebraska, Estados Unidos
- Research Site
-
-
Ohio
-
Sylvania, Ohio, Estados Unidos
- Research Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos
- Research Site
-
-
Oregon
-
Medford, Oregon, Estados Unidos
- Research Site
-
Portland, Oregon, Estados Unidos
- Research Site
-
-
Pennsylvania
-
Collegeville, Pennsylvania, Estados Unidos
- Research Site
-
Pittsburgh, Pennsylvania, Estados Unidos
- Research Site
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos
- Research Site
-
Clinton, South Carolina, Estados Unidos
- Research Site
-
-
Texas
-
Waco, Texas, Estados Unidos
- Research Site
-
-
Washington
-
Tacoma, Washington, Estados Unidos
- Research Site
-
-
-
-
-
Novosibirsk, Federación Rusa
- Research Site
-
Saint Petersburg, Federación Rusa
- Research Site
-
St. Petersburg, Federación Rusa
- Research Site
-
Vladikavkaz, Federación Rusa
- Research Site
-
-
Russia
-
Ekaterinburg, Russia, Federación Rusa
- Research Site
-
Moscow, Russia, Federación Rusa
- Research Site
-
-
-
-
-
Kochi, Japón
- Research Site
-
Kyoto, Japón
- Research Site
-
Oita, Japón
- Research Site
-
-
Fukuoka
-
Yanagawa, Fukuoka, Japón
- Research Site
-
-
Hiroshima
-
Hiroshima-shi, Hiroshima, Japón
- Research Site
-
-
Hokkaido
-
Asahikawa, Hokkaido, Japón
- Research Site
-
Chitose, Hokkaido, Japón
- Research Site
-
Kitahiroshima, Hokkaido, Japón
- Research Site
-
Obihiro, Hokkaido, Japón
- Research Site
-
Sapporo, Hokkaido, Japón
- Research Site
-
Tomakomai, Hokkaido, Japón
- Research Site
-
-
Hyogo
-
Himeji, Hyogo, Japón
- Research Site
-
-
Ibaraki
-
Naka-gun, Ibaraki, Japón
- Research Site
-
-
Kagawa
-
Sakaide, Kagawa, Japón
- Research Site
-
-
Kanagawa
-
Fujisawa-shi, Kanagawa, Japón
- Research Site
-
Yokohama, Kanagawa, Japón
- Research Site
-
-
Niigata
-
Nagaoka, Niigata, Japón
- Research Site
-
-
Oita
-
Beppu, Oita, Japón
- Research Site
-
-
Okayama
-
Kurashiki-shi, Okayama, Japón
- Research Site
-
-
Shimane
-
Matsue, Shimane, Japón
- Research Site
-
-
Tokyo
-
Chuo, Tokyo, Japón
- Research Site
-
Chuo-ku, Tokyo, Japón
- Research Site
-
Itabashi-ku, Tokyo, Japón
- Research Site
-
Kodaira, Tokyo, Japón
- Research Site
-
Nakano-ku, Tokyo, Japón
- Research Site
-
Ohota-ku, Tokyo, Japón
- Research Site
-
-
-
-
-
Guadalajara, México
- Research Site
-
-
Baja California
-
Tijuana, Baja California, México
- Research Site
-
-
D.f.
-
Mexico, D.f., México
- Research Site
-
-
Michoacan
-
Morelia, Michoacan, México
- Research Site
-
-
Nuevo Leon
-
Monterrey, Nuevo Leon, México
- Research Site
-
-
-
-
-
Brasov, Rumania
- Research Site
-
Bucharest, Rumania
- Research Site
-
Bucuresti, Rumania
- Research Site
-
Cluj Napoca, Rumania
- Research Site
-
Constanta, Rumania
- Research Site
-
Iasi, Rumania
- Research Site
-
Tg. Mures, Rumania
- Research Site
-
-
-
-
-
Amanzimtoti, Sudáfrica
- Research Site
-
Cape Town, Sudáfrica
- Research Site
-
Durban, Sudáfrica
- Research Site
-
Durbanville, Sudáfrica
- Research Site
-
Pretoria, Sudáfrica
- Research Site
-
Umkomaas, Sudáfrica
- Research Site
-
-
Centurion
-
Lyttleton, Centurion, Sudáfrica
- Research Site
-
-
Kwazulu Natal
-
Durban, Kwazulu Natal, Sudáfrica
- Research Site
-
-
-
-
-
Dnipropetrovsk, Ucrania
- Research Site
-
Donetsk, Ucrania
- Research Site
-
Kharkiv, Ucrania
- Research Site
-
Kyiv, Ucrania
- Research Site
-
Odesa, Ucrania
- Research Site
-
Poltava, Ucrania
- Research Site
-
Vinytsa, Ucrania
- Research Site
-
Zaporozhye, Ucrania
- Research Site
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Men and women. Women must be surgically sterilized/postmenopausal or use double barrier method contraception
- 6 months history of asthma according to ATS definition
- Prescribed daily dose of ICS and LABA for at least 3 months prior to Visit 2
- Pre-bronchodilator FEV1 of 40 to 85 % of predicted normal
- A total ACQ5 score of 1.5 or more
Exclusion Criteria:
- Respiratory infection significantly affecting the asthma
- Any significant disease and disorder that may put the patient at risk or influence study results
- Any clinically relevant abnormal findings
- A smoking history of more than 10 pack years
- Intake of oral, rectal or parenteral glucocorticosteroids
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Comparador de placebos: Placebo
|
Placebo to match AZD1981
|
|
Experimental: AZD1981 10 mg
|
AZD1981 twice daily
AZD1981 once daily
|
|
Experimental: AZD1981 40 mg
|
AZD1981 twice daily
AZD1981 once daily
|
|
Experimental: AZD1981 100 mg
|
AZD1981 twice daily
AZD1981 once daily
|
|
Experimental: AZD1981 400 mg
|
AZD1981 twice daily
AZD1981 once daily
|
|
Experimental: AZD1981 80 mg
|
AZD1981 twice daily
AZD1981 once daily
|
|
Experimental: AZD1981 200 mg
|
AZD1981 twice daily
AZD1981 once daily
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Pre-bronchodilator FEV1 at the Clinic
Periodo de tiempo: Twelve week treatment period
|
Change from baseline: treatment period average minus baseline.
Treatment period average defined as the mean of all available data during randomized treatment that occurred on or prior to treatment failure.
Treatment failure defined as worsening asthma symptoms resulting in increased dose of inhaled corticosteroid.
|
Twelve week treatment period
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Morning and Evening PEF
Periodo de tiempo: Twelve week treatment period
|
Change from baseline: treatment period average minus baseline.
Treatment period average defined as the mean of all available morning (evening) PEF during randomized treatment that occurred on or prior to treatment failure.
Treatment failure defined as worsening asthma symptoms resulting in increased dose of inhaled corticosteroid.
|
Twelve week treatment period
|
|
Asthma Control Questionnaire 5-item (ACQ5)
Periodo de tiempo: Twelve week treatment period
|
The ACQ5 consists of 5 questions, each assessed on a scale from 0-6, where 0 represents good asthma control and 6 represents poor asthma control.
The overall score is the mean of the responses.
The minimal important difference is defined as a change in score of 0.5.
Change from baseline: treatment period average minus baseline.
|
Twelve week treatment period
|
|
Adverse Events
Periodo de tiempo: Twelve week treatment period
|
Number of participants who had at least one adverse event during the randomized treatment period
|
Twelve week treatment period
|
|
Number of Participants With at Least One Severe Asthma Exacerbation
Periodo de tiempo: Twelve week treatment period
|
Severe asthma exacerbation defined as deterioration in asthma leading to either hospitalization/emergency room treatment or oral glucocorticosteroid treatment for at least 3 days
|
Twelve week treatment period
|
|
Number of Participants With at Least One Treatment Failure
Periodo de tiempo: Twelve week treatment period
|
Treatment failure is defined as a clinical need for additional inhaled corticosteroid use as judged by the investigator based on evaluations at the clinic.
|
Twelve week treatment period
|
|
Number of Participants With Well-controlled Asthma (ACQ5<=0.75)
Periodo de tiempo: Twelve week treatment period
|
The ACQ5 consists of 5 questions, each assessed on a scale from 0-6, where 0 represents good asthma control and 6 represents poor asthma control.
The overall score is the mean of the responses.
Well-controlled asthma is defined as ACQ5<=0.75 at the end of the 12-week treatment period.
|
Twelve week treatment period
|
|
Asthma Quality of Life Questionnaire (AQLQ(S))
Periodo de tiempo: Twelve week treatment period
|
The AQLQ(S) consists of 32 questions, each assessed on a scale from 1-7, with higher values indicating better health-related quality of life.
Overall scores are calculated from the means of the individual scores.
The minimal important difference is a change in score of 0.5.
Change from baseline: treatment period average minus baseline.
|
Twelve week treatment period
|
|
Asthma Symptom Score
Periodo de tiempo: Twelve week treatment period
|
Asthma symptoms, measured in the morning and evening, based on a scale from 0-3 with higher scores indicating more severe asthma symptoms.
Total asthma symptom score (0-6) is calculated by taking the sum of the morning and evening scores.
Change from baseline: treatment period average minus baseline.
|
Twelve week treatment period
|
|
Total Reliever Medication Use
Periodo de tiempo: Twelve week treatment period
|
Reliever medication use (number of inhalations), measured in the morning and evening.
Total reliever medication use is calculated by taking the sum of the number of daytime and evening inhalations of reliever medication.
Change from baseline: treatment period average minus baseline.
|
Twelve week treatment period
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Director de estudio: Chris O'Brien, MD, AstraZeneca
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización primaria
Finalización del estudio (Actual)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- D9830C00008
- 2010-020407-73 (Número EudraCT)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .